Lonza to Showcase Its Latest Solutions for Enhanced QC Testing and Transfection at SLAS2018. At Booth 534 Lonza will showcase how its automated QC testing solutions and Nucleofector™ Devices can ...

Lonza agreed to buy a manufacturing facility in the U.S. from Roche for around $1.2 billion in cash as it seeks to grow its biologics division. Lonza said the acquisition will help drive annual ...

(Reuters) -Swiss contract drug manufacturer Lonza said on Wednesday it would buy one of the world's largest manufacturing sites for biologic drugs in California from drugmaker Roche for $1.2 billion.

Lonza on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss drug contract manufacturer backed its growth ...

Lonza is poised for growth amid margin recovery, onshoring opportunities, and strong profit projections. Read more on LZAGY stock here.

Lonza, the Swiss Biotech firm that purchased Vacaville’s Genentech plant from Roche in 2024, released a streamlined operating model and invitations to its Annual General Meeting in Basel ...

Lonza shares rise 6.7% after CHI exit announcement Company to focus on CDMO business restructuring Plans M&A for tech and capacity opportunities Dec 12 (Reuters) - Swiss contract drugmaker Lonza ...

Swiss CDMO powerhouse Lonza is on a roll. Right after revealing a manufacturing expansion set to create nearly 200 new jobs, the CDMO has unveiled an expanded collaboration with an unnamed ...

Based on Lonza’s existing mammalian drug substance capacity and its estimated contribution to the firm’s overall business , William Blair analysts figure the company can generate about 1.6 ...